Moleculin Biotech Inc
MBRX
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.37M
Close$
$0.72
70.8% downside
Current Fair Value
70.8% downsideOvervalued by 70.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.37 Million |
|---|---|
| Enterprise Value | $-6,758,555.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-28.42 |
| Beta | 1.74 |
| Outstanding Shares | 41,244,820 |
Return
| Return on Equity | -199.78% |
|---|---|
| Return on Assets | -129.83% |
| Return on Invested Capital | -48.96% |
Valuation & Multiples
| P/E Ratio | -3.79 |
|---|---|
| PEG | -3.81 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 0.9 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -0.03 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 14, 2026
EPS Estimate
$-1.69
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 11, 2026
EPS Estimate
$-1.54
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.37%▼ 0.43% |
|---|---|
| Total Invested | $347,908▲ 10.39% |
| Investors Holding | 20▲ 3.00% |
ESG Score
No data
About Moleculin Biotech Inc
13 employeesMoleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of a broad portfolio of oncology drug candidates for the treatment of highly resistant tumors and viruses. The Company's clinical stage drugs a...